Crescita Therapeutics Inc (CTX) - Net Assets
Based on the latest financial reports, Crescita Therapeutics Inc (CTX) has net assets worth CA$15.58 Million CAD (≈ $11.27 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$20.33 Million ≈ $14.70 Million USD) and total liabilities (CA$4.75 Million ≈ $3.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$15.58 Million |
| % of Total Assets | 76.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -24.12% |
| 10-Year Change | -41.9% |
| Growth Volatility | 23.78 |
Crescita Therapeutics Inc - Net Assets Trend (2014–2025)
This chart illustrates how Crescita Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Crescita Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Crescita Therapeutics Inc (2014–2025)
The table below shows the annual net assets of Crescita Therapeutics Inc from 2014 to 2025. For live valuation and market cap data, see CTX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$15.58 Million ≈ $11.27 Million |
-1.60% |
| 2024-12-31 | CA$15.83 Million ≈ $11.45 Million |
-15.90% |
| 2023-12-31 | CA$18.82 Million ≈ $13.62 Million |
-10.78% |
| 2022-12-31 | CA$21.10 Million ≈ $15.26 Million |
+2.78% |
| 2021-12-31 | CA$20.53 Million ≈ $14.85 Million |
-2.87% |
| 2020-12-31 | CA$21.13 Million ≈ $15.29 Million |
+0.12% |
| 2019-12-31 | CA$21.11 Million ≈ $15.27 Million |
+11.05% |
| 2018-12-31 | CA$19.01 Million ≈ $13.75 Million |
+45.01% |
| 2017-12-31 | CA$13.11 Million ≈ $9.48 Million |
-51.11% |
| 2016-12-31 | CA$26.81 Million ≈ $19.39 Million |
+896.43% |
| 2015-12-31 | CA$-3.37 Million ≈ $-2.43 Million |
-60.21% |
| 2014-12-31 | CA$-2.10 Million ≈ $-1.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Crescita Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4544100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$51.49 Million | 330.57% |
| Other Comprehensive Income | CA$1.12 Million | 7.18% |
| Other Components | CA$8.41 Million | 53.99% |
| Total Equity | CA$15.58 Million | 100.00% |
Crescita Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Crescita Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SolGold PLC
LSE:SOLG
|
$10.25 Million |
|
Highfield Resources Ltd
F:23H
|
$10.25 Million |
|
Checkin.com Group AB
ST:CHECK
|
$10.26 Million |
|
Zoom2u Technologies Ltd
AU:Z2U
|
$10.26 Million |
|
Metallis Resources Inc.
V:MTS
|
$10.23 Million |
|
Scandinavian ChemoTech AB Series B
ST:CMOTEC-B
|
$10.22 Million |
|
The Motor & General Finance Limited
NSE:MOTOGENFIN
|
$10.22 Million |
|
Palash Securities Limited
NSE:PALASHSECU
|
$10.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Crescita Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,829,000 to 15,576,000, a change of -253,000 (-1.6%).
- Net loss of 92,000 reduced equity.
- Share repurchases of 223,000 reduced equity.
- Other comprehensive income increased equity by 10,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-92.00K | -0.59% |
| Share Repurchases | CA$223.00K | -1.43% |
| Other Comprehensive Income | CA$10.00K | +0.06% |
| Other Changes | CA$52.00K | +0.33% |
| Total Change | CA$- | -1.60% |
Book Value vs Market Value Analysis
This analysis compares Crescita Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.92x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CA$-0.20 | CA$0.76 | x |
| 2015-12-31 | CA$-0.29 | CA$0.76 | x |
| 2016-12-31 | CA$2.09 | CA$0.76 | x |
| 2017-12-31 | CA$0.94 | CA$0.76 | x |
| 2018-12-31 | CA$0.96 | CA$0.76 | x |
| 2019-12-31 | CA$0.94 | CA$0.76 | x |
| 2020-12-31 | CA$1.01 | CA$0.76 | x |
| 2021-12-31 | CA$0.99 | CA$0.76 | x |
| 2022-12-31 | CA$1.00 | CA$0.76 | x |
| 2023-12-31 | CA$0.93 | CA$0.76 | x |
| 2024-12-31 | CA$0.82 | CA$0.76 | x |
| 2025-12-31 | CA$0.83 | CA$0.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Crescita Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.44%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 1.31x
- Recent ROE (-0.59%) is above the historical average (-12.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -1759.16% | 0.51x | 0.00x | CA$-14.39 Million |
| 2015 | 0.00% | -1802.57% | 0.72x | 0.00x | CA$-15.11 Million |
| 2016 | -55.76% | -426.60% | 0.08x | 1.60x | CA$-17.63 Million |
| 2017 | -87.46% | -95.41% | 0.53x | 1.72x | CA$-12.77 Million |
| 2018 | 12.61% | 14.41% | 0.60x | 1.45x | CA$495.30K |
| 2019 | 8.79% | 8.30% | 0.83x | 1.27x | CA$-255.80K |
| 2020 | 0.18% | 0.24% | 0.58x | 1.27x | CA$-2.08 Million |
| 2021 | -5.38% | -6.59% | 0.58x | 1.41x | CA$-3.16 Million |
| 2022 | 4.09% | 3.66% | 0.83x | 1.35x | CA$-1.25 Million |
| 2023 | -10.55% | -11.33% | 0.71x | 1.31x | CA$-3.87 Million |
| 2024 | -17.37% | -14.04% | 0.90x | 1.38x | CA$-4.33 Million |
| 2025 | -0.59% | -0.44% | 1.04x | 1.31x | CA$-1.65 Million |
Industry Comparison
This section compares Crescita Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $739,937,582
- Average return on equity (ROE) among peers: -40.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Crescita Therapeutics Inc (CTX) | CA$15.58 Million | 0.00% | 0.31x | $10.23 Million |
| Aurora Cannabis Inc (ACB) | $601.87 Million | -11.52% | 0.39x | $193.63 Million |
| Amotiv Limited (AOV) | $915.11 Million | 1.59% | 0.43x | $553.67 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-4.29 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $841.07K | -309.08% | 1.52x | $13.17 Million |
| Avant Brands Inc (AVNT) | $-490.96K | 0.00% | 0.00x | $4.13 Million |
| Bausch Health Companies Inc (BHC) | $5.23 Billion | -16.55% | 4.34x | $2.06 Billion |
| CanadaBis Capital Inc (CANB) | $150.00K | 0.00% | 0.00x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $550.08 Million | -25.79% | 1.50x | $12.59 Million |
| Cipher Pharmaceuticals Inc (CPH) | $80.52 Million | 25.31% | 0.07x | $326.62 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $22.27 Million | -71.36% | 0.11x | $148.65 Million |
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers an… Read more